Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026

Allegations concern two GUTS public offerings in August and September 2025 that generated approximately $76.7 million in net proceeds. The claims assert that GUTS shares traded at artificially inflated levels based on the company’s interim Revita data, creating potential litigation and credibility risks for the biotech company.